2.
青少年脊柱侧凸患者发生PONV的单因素分析结果
Univariate analysis of the factors affecting PONV inAIS patients
| Variable | PONV | P | Variable | PONV | P | ||
| Yes | No | Yes | No | ||||
| PONV: Postoperative nausea and vomiting; BMI: Body mass index; ASA: American Society of Anesthesiologists; MAP: Mean arterial pressure; CVP: Central venous pressure; ΔHb: Hb gap before and after operation; PCIA: Patient controlled intravenous analgesia. | |||||||
| Gender [n, (%)] | 0.808 | ||||||
| Male | 18 (11.9%) | 138 (16.5%) | Fentanyl dosage (mg, Mean±SD) |
0.81±0.14 | 0.54±0.07 | <0.01 | |
| Female | 133 (88.1%) | 697 (83.5%) | |||||
| BMI [kg/m2, (%)] | 0.413 | Colloid dosage (mL, Mean±SD) |
1292.72±445.17 | 1333.29±469.41 | 0.441 | ||
| BMI≤15 | 9 (6.0%) | 44 (5.3%) | Crystalloid dosage (mL, Mean±SD) |
1518.54±439.76 | 1662.92±515.44 | <0.01 | |
| 15 < BMI≤18 | 81 (53.6%) | 361 (43.2%) | Blood transfusion volume (mL, Mean±SD) |
820.11±653.93 | 882.61±648.95 | 0.995 | |
| 18 < BMI≤23 | 58 (38.4%) | 385 (46.1%) | Blood loss (mL, Mean±SD) | 898.08±633.74 | 981.62±599.01 | 0.901 | |
| BMI＞23 | 3 (2.0%) | 45 (5.4%) | Urine volume (mL, Mean±SD) |
1180.13±483.12 | 1236.06±530.83 | 0.173 | |
| ASA grade [n, (%)] | 0.537 | MAP (mmHg, Mean±SD) | 68.52±5.05 | 68.97±4.82 | 0.200 | ||
| Ⅰ | 85 (56.3%) | 431 (51.6%) | CVP (mmHg, Mean±SD) | 5.16±2.64 | 5.32±2.59 | 0.988 | |
| Ⅱ | 64 (42.4%) | 388 (46.5%) | Dexmedetomidine | ||||
| Ⅲ | 2 (1.3%) | 16 (1.9%) | Administered | 80 (53.0%) | 562 (67.3%) | 0.001 | |
| Cobb angle[°, (%)] | 0.195 | ||||||
| ≥90 | 3 (2.0%) | 7(0.8%) | Non-administered | 71 (47.0%) | 273 (32.7%) | ||
| < 90 | 148 (98.0%) | 828 (99.2%) | ΔHb (g/L, Mean±SD) | 33.67±14.96 | 31.68±15.39 | 0.072 | |
| Preoperative cardiac | 0.944 | PCIA [n, (%)] | 66 (43.7%) | 220 (26.3%) | <0.01 | ||
| disease [n, (%)] | Administered | ||||||
| Exist | 9 (6.0%) | 51 (6.1%) | Non-administered | 85 (56.3%) | 615 (73.7%) | ||
| None | 142 (94.0%) | 784 (93.9%) | |||||
| Preoperative respiratory | 0.073 | Operation time (h) | 0.712 | ||||
| disease [n, (%)] | 25 (16.6%) | 95 (11.4%) | ≥5 | 30 | 177 | ||
| Exist | 126 (83.4%) | 740 (88.6%) | < 5 | 121 | 658 | ||
| None | Dexamethasone [n, (%)] | 0.028 | |||||
| Type of anesthesia [n, (%)] | 0.344 | Administered | 87 (57.6%) | 400 (47.9%) | |||
| Intravenous | 128 (84.8%) | 681 (81.6%) | Non-administered | 64 (42.4%) | 435 (52.1%) | ||
| Combined intravenous | 23 (15.2%) | 154 (18.4%) | Dexamethasone+ondansetron | ||||
| and inhalation | +droperidol[n, (%)] | 0.927 | |||||
| Dexamethasone+ | <0.01 | Administered | 2 (1.3%) | 12 (1.4%) | |||
| ondansetron [n, (%)] | Non-administered | 149 (98.7%) | 833 (98.6%) | ||||
| Administered | 39 (25.8%) | 390 (46.7%) | |||||
| Non-administered | 112 (74.2%) | 445 (53.3%) | |||||